Targets › CEPE
1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 4; Hematology, Infectious disease; next expected readout May 2029.
Open in Phaseline: the race on CEPE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Orchid Pharma Europe | Cefepime Bacterial penicillin-binding protein inhibitor | CEPE, ENME | Phase 2 | Complicated Urinary Tract Infection; Infection; Intestinal Microbiome | May 2029 |
Complicated Urinary Tract Infection (1) Infection (1) Intestinal Microbiome (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.